Melphalan Hydrochloride Patent Expiration
Melphalan Hydrochloride was first introduced by Apotex Inc
Melphalan Hydrochloride Patents
Given below is the list of patents protecting Melphalan Hydrochloride, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Ivra | US10537520 | Stable liquid formulations of melphalan | Jun 29, 2036 | Apotex |
| Hepzato | US9707331 | Apparatus for removing chemotherapy compounds from blood | Sep 17, 2034 | Delcath Systems Inc |
| Hepzato | US9314561 | Filter and frame apparatus and method of use | Feb 07, 2034 | Delcath Systems Inc |
| Evomela | US10040872 | Alkylated cyclodextrin compositions and processes for preparing and using the same | Jan 30, 2034 | Acrotech Biopharma |
| Evomela | US9493582 | Alkylated cyclodextrin compositions and processes for preparing and using the same | Feb 27, 2033 | Acrotech Biopharma |
| Hepzato | US10195334 | Filter and frame apparatus and method of use | Jan 16, 2033 | Delcath Systems Inc |
| Hepzato | US11083831 | Filter and frame apparatus and method of use | Dec 30, 2032 | Delcath Systems Inc |
| Hepzato | US11833286 | Filter and frame apparatus and method of use | Dec 30, 2032 | Delcath Systems Inc |
| Hepzato | US10098997 | Apparatus for removing chemotherapy compounds from blood | Nov 07, 2032 | Delcath Systems Inc |
| Hepzato | US10369264 | Apparatus for removing chemotherapy compounds from blood | Nov 07, 2032 | Delcath Systems Inc |
| Hepzato | US10569004 | Apparatus for removing chemotherapy compounds from blood | Nov 07, 2032 | Delcath Systems Inc |
| Hepzato | US11241522 | Apparatus for removing chemotherapy compounds from blood | Nov 07, 2032 | Delcath Systems Inc |
| Hepzato | US11633528 | Apparatus for removing chemotherapy compounds from blood | Nov 07, 2032 | Delcath Systems Inc |
| Evomela | US10940128 | Injectable melphalan compositions comprising a cyclodextrin derivative and methods of making and using the same | Jun 14, 2030 | Acrotech Biopharma |
| Evomela | US10864183 | Injectable nitrogen mustard compositions comprising a cyclodextrin derivative and methods of making and using the same | May 28, 2030 | Acrotech Biopharma |
| Evomela | US11020363 | Injectable nitrogen mustard compositions comprising a cyclodextrin derivative and methods of making and using the same | May 28, 2030 | Acrotech Biopharma |
| Evomela | US8410077 | Sulfoalkyl ether cyclodextrin compositions | Mar 13, 2029 | Acrotech Biopharma |
| Evomela | US9200088 | Sulfoalkyl ether cyclodextrin compositions | Mar 13, 2029 | Acrotech Biopharma |
A patent's expiry date may change depending upon legal activities going on that patent. Critical
activities like
abandoning of a patent, term extension of a patent or amendment of its claims can increase or
decrease the life of a
patent hence affecting its expiry date and in turn affecting the generic launch date of that
drug. Tracking these
ongoing activities on a patent application helps to keep an eye on the latest developments in
the patent process of
the drug which can give an idea of how early a drug's generic could be available. The next
section provides a list
of recent legal activities on Melphalan Hydrochloride's patents.
Latest Legal Activities on Melphalan Hydrochloride's Patents
Given below is the list recent legal activities going on the following patents of Melphalan Hydrochloride.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 4th Yr, Small Entity | 23 Jan, 2023 | US10537520 |
| Post Issue Communication - Certificate of Correction | 31 Jan, 2020 | US10537520 |
| Recordation of Patent Grant Mailed Critical
| 21 Jan, 2020 | US10537520 |
| Patent Issue Date Used in PTA Calculation Critical
| 21 Jan, 2020 | US10537520 |
| Issue Notification Mailed Critical
| 01 Jan, 2020 | US10537520 |
| Dispatch to FDC | 16 Dec, 2019 | US10537520 |
| Application Is Considered Ready for Issue Critical
| 16 Dec, 2019 | US10537520 |
| Issue Fee Payment Received Critical
| 03 Dec, 2019 | US10537520 |
| Issue Fee Payment Verified Critical
| 03 Dec, 2019 | US10537520 |
| Printer Rush- No mailing | 02 Dec, 2019 | US10537520 |
Melphalan Hydrochloride's Family Patents
